Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruiting
NCT07402915Phase 1Updated Jul 7, 2026
Sponsor: AstraZeneca
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal
Georgia, Ireland, Portugal, Spain
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C LevelsCompleted
NCT07423598Phase 1Updated Jul 7, 2026
Sponsor: AstraZeneca
Healthy Participants
United States
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.Completed
NCT06750276Phase 2Updated Jul 6, 2026
Sponsor: AstraZeneca
Liver Fibrosis · Hepatic Cirrhosis
United States, Puerto Rico, United Kingdom
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive Not Recruiting
NCT06764186Phase 3Updated Jul 6, 2026
Sponsor: AstraZeneca
Locally Advanced or Metastatic Breast Cancer
Spain
Study of AZD2811 + Durvalumab in ES-SCLCActive Not Recruiting
NCT04745689Phase 2Updated Jul 6, 2026
Sponsor: AstraZeneca
Small-Cell Lung Cancer
United States, Poland, South Korea, Spain
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy ParticipantsNot Yet Recruiting
NCT07685600Phase 1Updated Jul 6, 2026
Sponsor: AstraZeneca
Healthy
Advanced Robotic Techniques and Rapid Onsite Evaluation for Minimally Invasive Diagnosis and Next-Generation Sequencing.Not Yet Recruiting
NCT07685977NAUpdated Jul 6, 2026
Sponsor: Vanderbilt University Medical Center
Peripheral Pulmonary Lesions (PPLs)
United States
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruiting
NCT06535607Phase 2Updated Jul 6, 2026
Sponsor: AstraZeneca
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) · Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
United States, Australia, Brazil, Canada, China +7 more
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive Not Recruiting
NCT05120349Phase 3Updated Jul 6, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Argentina, Brazil, Canada, China +15 more
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary AldosteronismRecruiting
NCT07007793Phase 3Updated Jul 6, 2026
Sponsor: AstraZeneca
Primary Hyperaldosteronism
United States, Australia, Canada, China, France +7 more
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)Active Not Recruiting
NCT05460273Phase 1, Phase 2Updated Jul 2, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Cancer
China
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentRecruiting
NCT07343960Phase 1Updated Jul 2, 2026
Sponsor: AstraZeneca
Moderate Hepatic Impairment
United States
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventRecruiting
NCT07000357Phase 3Updated Jul 2, 2026
Sponsor: AstraZeneca
Cardiovascular Disease
United States, Argentina, Brazil, Bulgaria, Canada +31 more
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive Not Recruiting
NCT05775159Phase 2Updated Jul 2, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma · Biliary Tract Cancer
United States, China, Hong Kong, Italy, Japan +4 more
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightActive Not Recruiting
NCT07017179Phase 2Updated Jul 2, 2026
Sponsor: AstraZeneca
Obesity/Overweight
China
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active Not Recruiting
NCT03330847Phase 2Updated Jul 2, 2026
Sponsor: AstraZeneca
Metastatic Triple Negative Breast Cancer
United States, Belgium, Canada, Czechia, France +10 more
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaNot Yet Recruiting
NCT07681596Phase 1, Phase 2Updated Jul 2, 2026
Sponsor: AstraZeneca
Relapsed or Refractory Multiple Myeloma
United States, Australia
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive Not Recruiting
NCT06008093Phase 2Updated Jul 2, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
United States
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)Completed
NCT04609904Phase 3Updated Jul 2, 2026
Sponsor: AstraZeneca
Asthma
United States, Brazil, China, Colombia, Czechia +11 more
Study of AZD9829 in CD123+ Hematological MalignanciesCompleted
NCT06179511Phase 1, Phase 2Updated Jul 1, 2026
Sponsor: AstraZeneca
Hematological Malignancies
United States, Australia, China, Germany, Italy +5 more
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot Yet Recruiting
NCT06855225Phase 2Updated Jul 1, 2026
Sponsor: Mehmet Akce
Combined Hepatocellular and Cholangiocarcinoma
United States
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsRecruiting
NCT07291037Phase 3Updated Jul 1, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
United States, Australia, Austria, Belgium, Brazil +16 more
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Recruiting
NCT07431281Phase 3Updated Jul 1, 2026
Sponsor: AstraZeneca
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal Cancer
United States, Australia, Austria, Belgium, Brazil +17 more
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)Recruiting
NCT07611110Phase 3Updated Jul 1, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Australia, Austria, Brazil, Canada +12 more
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)Recruiting
NCT07098338Phase 2Updated Jul 1, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Australia, Canada, China, France +7 more

Previous page Next page